Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Providence Cancer Center at Holy Family Hospital
mi
from
Spokane, WA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Providence Cancer Center at Holy Family Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2015
Southwest Oncology Group
mi
from
San Antonio, TX
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2015
Southwest Oncology Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Chicago, IL
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib
Status: Enrolling
Updated:  8/12/2015
15
mi
from
Concord,
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib
Status: Enrolling
Updated: 8/12/2015
15
mi
from
Concord,
Click here to add this to my saved trials
Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection
A Prospective Randomized Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection
Status: Enrolling
Updated:  8/12/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection
A Prospective Randomized Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection
Status: Enrolling
Updated: 8/12/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  8/12/2015
CCF-Willoughby Hills
mi
from
Willoughby Hills, OH
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 8/12/2015
CCF-Willoughby Hills
mi
from
Willoughby Hills, OH
Click here to add this to my saved trials
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  8/12/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 8/12/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Status: Enrolling
Updated:  8/12/2015
The Ohio State University, College of Dentistry
mi
from
Columbus, OH
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Status: Enrolling
Updated: 8/12/2015
The Ohio State University, College of Dentistry
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Status: Enrolling
Updated:  8/12/2015
University of Louisville, School of Dentistry
mi
from
Louisville, KY
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Status: Enrolling
Updated: 8/12/2015
University of Louisville, School of Dentistry
mi
from
Louisville, KY
Click here to add this to my saved trials
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Status: Enrolling
Updated:  8/12/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Status: Enrolling
Updated: 8/12/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Evaluating Attenuation Correction Methods Applied to PET/MRI
Status: Enrolling
Updated:  8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Evaluating Attenuation Correction Methods Applied to PET/MRI
Status: Enrolling
Updated: 8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer
PET Using Hormone Receptor Ligands in Breast Cancer
Status: Enrolling
Updated:  8/12/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer
PET Using Hormone Receptor Ligands in Breast Cancer
Status: Enrolling
Updated: 8/12/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Southern Cancer Center
mi
from
Mobile, AL
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Southern Cancer Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
VA San Diego Healthcare System
mi
from
San Diego, CA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
VA San Diego Healthcare System
mi
from
San Diego, CA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Edward Alexson, Md, Inc.
mi
from
Santa Ana, CA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Edward Alexson, Md, Inc.
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Connecticut Oncology Group
mi
from
Middletown, CT
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Connecticut Oncology Group
mi
from
Middletown, CT
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
University of Chicago
mi
from
Chicago, IL
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Cancer Center of Kansas
mi
from
Wichita, KA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Jackson Oncology Associates
mi
from
Jackson, MS
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Jackson Oncology Associates
mi
from
Jackson, MS
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Summa Health System
mi
from
Akron, OH
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Summa Health System
mi
from
Akron, OH
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Associates In Hematology & Oncology, P.C.
mi
from
Upland, PA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Associates In Hematology & Oncology, P.C.
mi
from
Upland, PA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Cancer Specialists Of South Texas, Pa
mi
from
Corpus Christi, TX
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Cancer Specialists Of South Texas, Pa
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Dean Hematology And Oncology Clinic
mi
from
Madison, WI
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Dean Hematology And Oncology Clinic
mi
from
Madison, WI
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Compassionate Cancer Care Medical Group
mi
from
Riverside, CA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Compassionate Cancer Care Medical Group
mi
from
Riverside, CA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Gwinnett Hospital System Inc.
mi
from
Lawrenceville, GA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Gwinnett Hospital System Inc.
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Midwestern Regional Medical Center
mi
from
Zion, IL
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Midwestern Regional Medical Center
mi
from
Zion, IL
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Tufts Medical Center
mi
from
Boston, MA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
North Mississippi Hematology And Oncology Associates, Ltd
mi
from
Tupelo, MS
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
North Mississippi Hematology And Oncology Associates, Ltd
mi
from
Tupelo, MS
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
New York Oncology Hematology PC
mi
from
Albany, NY
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Samuel S Stratton VAMC
mi
from
Albany, NY
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Samuel S Stratton VAMC
mi
from
Albany, NY
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials